MicroRNA-93 Identified as Potential Therapeutic Target for Fatty Liver Disease

Targeting miR-93 to Address Fatty Liver Disease

Metabolic dysfunction-associated steatotic liver disease affects approximately one in three people of the global population, yet treatment options remain constrained. A research team led by Jang Hyun Choi at the UNIST institute, alongside collaborators from Pusan National University and Ulsan University Hospital, has uncovered a molecular mechanism that regulates how the liver processes fats. The team identified a small RNA molecule, microRNA-93 (miR-93), which appears to act as a central switch in the development of the disease.

This elevation disrupts hepatic fat metabolism by blocking SIRT1, a gene responsible for regulating energy use. When SIRT1 is suppressed, the liver shifts from burning fat to storing it, while also impairing the organ’s ability to maintain energy balance during stress.

In experiments with mice incapable of producing miR-93, researchers observed significant improvements. Even when subjected to a high-fat and high-fructose diet, these subjects showed reduced liver fat accumulation, better glycemic control, and enhanced mitochondrial function. To find a practical intervention, the team screened 150 already-approved medications and identified niacin, or vitamin B3, as the most effective candidate for lowering miR-93 levels and restoring SIRT1 activity.

Positive Affect Treatment (PAT) and the Management of Anhedonia

The efficacy of this approach was tested in a randomized clinical trial involving 98 adults suffering from severe anhedonia, depression, and anxiety. The findings, published in the journal JAMA Network Open, indicate that patients receiving PAT showed greater improvements in their overall clinical state compared to those undergoing conventional, negative-emotion-focused therapy. Notably, these benefits remained evident one month after the conclusion of the treatment. Researchers emphasize that while these results are encouraging, they stem from a single, modest-sized trial and require further confirmation.

Clinical Considerations and Future Directions

Both the liver research and the psychological study highlight a move toward repurposing or reframing existing tools to address complex, chronic conditions. In the case of liver disease, niacin is already a well-established medication for managing high cholesterol, making it a strong candidate for potential therapeutic repositioning. However, researchers caution that clinical trials in human patients are essential, particularly because high doses of niacin can cause adverse side effects that require careful medical oversight.

For patients dealing with the conditions discussed here, these developments underscore the importance of professional guidance. Whether considering new metabolic approaches or behavioral therapies like PAT, patients should consult their healthcare providers to discuss the suitability of these options for their individual health profiles. As the scientific community continues to explore these pathways, the focus remains on confirming these early findings through more comprehensive clinical research.